The University of Southampton
University of Southampton Institutional Repository

ω-3 LCPUFA supplementation during pregnancy and risk of allergic outcomes or sensitization in offspring

ω-3 LCPUFA supplementation during pregnancy and risk of allergic outcomes or sensitization in offspring
ω-3 LCPUFA supplementation during pregnancy and risk of allergic outcomes or sensitization in offspring
Background - Allergic diseases have increased worldwide in the last 2 decades, with children suffering the highest burden of the condition. The ω-3 long-chain poly-unsaturated fatty acid (LCPUFA) possesses anti-inflammatory properties that could lead to a reduction in inflammatory mediators in allergies.Objective - A systematic review and meta-analysis of the most recent follow-ups of randomized clinical trials (RCTs) was conducted to assess the effectiveness of ω-3 LCPUFA supplementation started during pregnancy on allergic outcomes in offspring.Methods - The RCTs with a minimum of 1-month follow-up post gestation were eligible for inclusion. The CENTRAL, MEDLINE, SCOPUS, WHO's International Clinical Trials Register, E-theses, and Web of Science databases were searched. Study quality was evaluated using the Cochrane Collaboration's risk of bias tool.Results - Ten RCTs (3,637 children), from 9 unique trials, examined the effectiveness of ω-3 LCPUFA supplementation started during pregnancy on the development of allergic outcomes in offspring. Heterogeneities were seen between the trials in terms of their sample, type, and duration of intervention and follow-up. Pooled estimates showed a significant reduction in childhood “sensitization to egg” (relative risk [RR] = 0.54, 95% confidence interval [CI] = 0.32-0.90), and “sensitization to peanut” (RR = 0.62, 95% CI = 0.40-0.96). No statistical differences were found for other allergic outcomes (eg, eczema, asthma/wheeze).Conclusion - These results suggest that intake of ω-3 LCPUFA started during pregnancy can reduce the risk of sensitization to egg and peanut; however, the evidence is limited because of the small number of studies that contributed to the meta-analyses. The current evidence on the association between supplementation with ω-3 LCPUFA started during pregnancy and allergic outcomes is weak, because of the risk of bias and heterogeneities between studies.
1081-1206
302-313.e2
Vahdaninia, Mariam
e359d63b-01e4-4045-a23e-6f994339cfda
Mackenzie, Healther
e1e524b1-b525-4da4-a7d3-d0bb359f4680
Dean, Taraneh
1bb6a824-55c0-484a-a3f9-3f4ea60912fc
Helps, Suzannah
37a00136-23cb-4c1e-b6b0-7f1511695ad6
Vahdaninia, Mariam
e359d63b-01e4-4045-a23e-6f994339cfda
Mackenzie, Healther
e1e524b1-b525-4da4-a7d3-d0bb359f4680
Dean, Taraneh
1bb6a824-55c0-484a-a3f9-3f4ea60912fc
Helps, Suzannah
37a00136-23cb-4c1e-b6b0-7f1511695ad6

Vahdaninia, Mariam, Mackenzie, Healther, Dean, Taraneh and Helps, Suzannah (2018) ω-3 LCPUFA supplementation during pregnancy and risk of allergic outcomes or sensitization in offspring. Annals of Allergy, Asthma and Immunology, 122 (3), 302-313.e2. (doi:10.1016/j.anai.2018.12.008).

Record type: Article

Abstract

Background - Allergic diseases have increased worldwide in the last 2 decades, with children suffering the highest burden of the condition. The ω-3 long-chain poly-unsaturated fatty acid (LCPUFA) possesses anti-inflammatory properties that could lead to a reduction in inflammatory mediators in allergies.Objective - A systematic review and meta-analysis of the most recent follow-ups of randomized clinical trials (RCTs) was conducted to assess the effectiveness of ω-3 LCPUFA supplementation started during pregnancy on allergic outcomes in offspring.Methods - The RCTs with a minimum of 1-month follow-up post gestation were eligible for inclusion. The CENTRAL, MEDLINE, SCOPUS, WHO's International Clinical Trials Register, E-theses, and Web of Science databases were searched. Study quality was evaluated using the Cochrane Collaboration's risk of bias tool.Results - Ten RCTs (3,637 children), from 9 unique trials, examined the effectiveness of ω-3 LCPUFA supplementation started during pregnancy on the development of allergic outcomes in offspring. Heterogeneities were seen between the trials in terms of their sample, type, and duration of intervention and follow-up. Pooled estimates showed a significant reduction in childhood “sensitization to egg” (relative risk [RR] = 0.54, 95% confidence interval [CI] = 0.32-0.90), and “sensitization to peanut” (RR = 0.62, 95% CI = 0.40-0.96). No statistical differences were found for other allergic outcomes (eg, eczema, asthma/wheeze).Conclusion - These results suggest that intake of ω-3 LCPUFA started during pregnancy can reduce the risk of sensitization to egg and peanut; however, the evidence is limited because of the small number of studies that contributed to the meta-analyses. The current evidence on the association between supplementation with ω-3 LCPUFA started during pregnancy and allergic outcomes is weak, because of the risk of bias and heterogeneities between studies.

This record has no associated files available for download.

More information

Accepted/In Press date: 6 December 2018
e-pub ahead of print date: 12 December 2018
Published date: 12 December 2018

Identifiers

Local EPrints ID: 438692
URI: http://eprints.soton.ac.uk/id/eprint/438692
ISSN: 1081-1206
PURE UUID: fb35e5db-cc92-45f4-a66d-5a5b4cd2d26a
ORCID for Healther Mackenzie: ORCID iD orcid.org/0000-0002-5241-0007

Catalogue record

Date deposited: 20 Mar 2020 17:38
Last modified: 17 Mar 2024 03:59

Export record

Altmetrics

Contributors

Author: Mariam Vahdaninia
Author: Healther Mackenzie ORCID iD
Author: Taraneh Dean
Author: Suzannah Helps

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×